Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Walgreens coughs up nearly $6 mil. to settle with FTC

This article was originally published in The Tan Sheet

Executive Summary

Walgreens will pay nearly $6 million to settle charges with the Federal Trade Commission that the pharmacy chain deceptively advertised Wal-Born, a supplement similar to Airborne cold-and-flu products, the FTC said in a March 23 release. FTC says Walgreens advertised the product in newspaper circulars and online with " baseless claims" the supplements could prevent colds, fight germs and boost the immune system. Further, a federal court approved a settlement of $565,000 for Wal-Born manufacturer Improvita Health Products' two principal officers. FTC says Walgreens sold the supplements and marketed them with their similarities to Airborne, which FTC charged with deceptive advertising and settled in 2008 (1"The Tan Sheet" April 18, 2008). FTC's suit against Improvita is still being litigated. Improvita manufactured similar store-brand products for Rite Aid, which the FTC settled cases with in 2009

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel